A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design

Skin Irritation Clinical Trial

Official title:

A 21-Day, Randomized, Controlled Study to Evaluate the Irritation Potential of Diltiazem Hydrochloride 2% Cream in Healthy Subjects, Using a Cumulative Irritant Patch Test Design

Clinical Trial Details — Status: Unknown status

Administrative data

• NCT number: NCT01821274
• Other study ID #: VEN307-DERM-002
• Status: Unknown status
• Phase: Phase 1
• First received: March 26, 2013
• Last updated: August 19, 2013
• Start date: March 2013
• Est. completion date: September 2013

Study information

• Verified date: July 2013
• Source: Ventrus Biosciences, Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to determine whether Diltiazem Hydrochloride 2% Cream will cause irritation to skin on the back of healthy volunteers after repeated application over 21-days.

Description:

The primary objective of this study will be to determine the potential of Diltiazem Hydrochloride 2% Cream to cause irritation after repeated topical application to the healthy skin of humans under controlled conditions.

In addition, safety will be assessed by evaluation of any adverse events (AEs) reported during the study.

Recruitment information / eligibility

• Status: Unknown status
• Enrollment: 30
• Est. completion date: September 2013
• Est. primary completion date: July 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Are healthy males or females (to be confirmed by medical history)

• Are 18 years of age or older

• In the case of females of childbearing potential, are using an acceptable form of birth control (oral/implant/injectable/transdermal contraceptives, intrauterine device, condom with spermicide, diaphragm with spermicide, abstinence, partner's vasectomy). Abstinence or vasectomies are acceptable if the female subject agrees to implement one of the other acceptable methods of birth control if her lifestyle/partner changes

• If a female of childbearing potential, have a negative urine pregnancy test (UPT) at Screening, and are willing to submit to a pregnancy test at end of study (EOS)

• Are free of any systemic or dermatologic disorder, which, in the opinion of the investigator, will interfere with the study results or increase the risk of adverse events

• Are of any skin type or race, providing the skin pigmentation will allow discernment of erythema

• Complete a Medical Screening form as well as a Medical Personal History form

• Read, understand, and provide signed informed consent

Exclusion Criteria:

• Have sick sinus syndrome except in the presence of a functioning ventricular pacemaker (confirmed via medical history

• Have second-or third-degree AV block except in the presence of a functioning ventricular pacemaker (confirmed via medical history)

• Have hypotension (less than 90 mm Hg systolic, determined by performing vital signs)

• Have acute myocardial infarction and pulmonary congestion documented by x-ray (confirmed via medical history)

• Have any visible skin disease at the application site which, in the opinion of the investigative personnel, will interfere with the evaluation of the test site reaction

• Are not willing to refrain from using systemic/topical analgesics such as aspirin (81 mg daily aspirin will be allowed), Aleve, Motrin, Advil, or Nuprin for 72 hours prior to Day 1 and during the study (occasional use of acetaminophen will be permitted)

• Are using systemic/topical corticosteroids for 3 weeks prior to and during the study, or systemic/topical antihistamines for 72 hours prior to Day 1 and during the study

• Are using medication which, in the opinion of the investigative personnel, will interfere with the study results, including anti-inflammatory medications

• Are unwilling or unable to refrain from the use of sunscreens, cosmetics, creams, ointments, lotions, or similar products on the back during the study

• Have psoriasis and/or active atopic dermatitis/eczema

• Are females who are pregnant, plan to become pregnant during the study, or are breast-feeding a child

• Have a known sensitivity to constituents present in the material being evaluated

• Have damaged skin in or around the test sites, including sunburn, excessively deep tans, uneven skin tones, tattoos, scars, excessive hair, numerous freckles, or other disfigurations of the test site

• Have received treatment for any type of internal cancer within 5 years prior to study entry

• Have a history of, or are currently being treated for skin cancer

• Are currently participating in any clinical testing

• Have any known sensitivity to adhesives

• Have received any investigational treatment(s) within 4 weeks prior to study entry

Related Conditions & MeSH terms

• Skin Irritation

Intervention

Drug:
• Diltiazem Hydrochloride 2% Cream
0.2 g applied topically to the infrascapular area of the back.
• Vehicle Cream
0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
• 0.1% solution o sodium lauryl sulfate (SLS)
0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
• Saline 0.9%
0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.

Locations

Country	Name	City	State
United States	TKL Research	Paramus	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
Ventrus Biosciences, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mean cumulative irritation score of Diltiazem Hydrochloride 2% Cream in healthy skin of humans.	The primary variable of interest is the mean cumulative irritation score. The mean cumulative irritation score for each subject, product and site will be calculated as the sum of the irritation scores divided by the number of readings. The total cumulative irritation score for each subject and product will also be calculated as the sum of irritation scores on each of 21 evaluation days. A normalized total score for each patch will be calculated by summing the total irritation scores for all subjects, dividing by the number of readings and multiplying by 210. These parameters will be tested pairwise for product differences using Fisher's protected least significant differences in the context of the analysis of variance (ANOVA), including effects of subject and product (ie, randomized complete blocks). All pairwise differences will be tested. No adjustment for multiple comparisons will be made.	21 days